SAGE Therapeutics Appoints Howard H. Pien to the Company’s Board of Directors
SAGE Therapeutics Initiates Phase 1/2 Trial of SAGE-547 in Status Epilepticus
SAGE Therapeutics Closes $38M Oversubscribed Series C Financing
SAGE Therapeutics is a neuroscience-focused company developing medicines to treat life-threatening, rare CNS disorders. SAGE’s lead program, SAGE-547, is in clinical development for super-refractory status epilepticus (SRSE) and is the first of many compounds the company is developing in its portfolio of potential seizure medicines. SAGE’s robust chemistry platform has generated multiple new compounds that target the GABAA and NMDA receptors, which have demonstrated preclinical activity. SAGE Therapeutics is a private company launched in 2010 by an experienced team of R&D leaders, CNS experts and investors. For more information, please visit www.sagerx.com.